Vincent Woo - Concepedia

Author

Vincent Woo

Also Known As

David Caplan, Diana Sherifali, Heather Lochnan, Maritza Wong, Moses, Alan, Naresh Aggarwal, Richard E. Pratley, V Woo, V. C. Woo, V. Woo

195

Publications

22.6K

Citations

H-Index

Concepts

All Affiliations

University of Manitoba University of Toronto St. Michael's Hospital Western University Novo Nordisk (Denmark)

About

Vincent Woo is an author at University of Manitoba specializing in medicine, diabetes, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	25	9K
2	Public Health	14	15	5.3K
3	Health Sciences	1	1	29
4	Biochemistry	1	1	168
5	Cellular Physiology	1	1	168

Vincent Woo

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, The Lancet Diabetes ManagementCardiovascular DiseaseDiabetesClinical TrialsType 2	2018	1.7K
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes James F. List, Vincent Woo, Enrique Morales, Diabetes Care	2008	689
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children Kara Nerenberg, Kelly B. Zarnke, Alexander A. C. Leung, Canadian Journal of Cardiology Risk AssessmentBlood Pressure MonitoringHypertensionCardiovascular DiseaseHealth Policy	2018	575
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension Alexander A. C. Leung, Kara Nerenberg, Stella S. Daskalopoulou, Canadian Journal of Cardiology Blood Pressure MonitoringHypertensionBlood PressureCardiovascular DiseaseHealth Policy	2016	466
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes Stephen Gough, Bruce W. Bode, Vincent Woo, The Lancet Diabetes & Endocrinology Diabetes ManagementInsulin DegludecDiabetesPharmacologyClinical Trials	2014	351
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, The Lancet Diabetes & Endocrinology Diabetes ManagementSglt-2 Inhibitor TherapyMedicineDiabetesSustain 9	2019	336
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults Alexander A. C. Leung, Stella S. Daskalopoulou, Kaberi Dasgupta, Canadian Journal of Cardiology Risk AssessmentBlood Pressure MonitoringHypertensionPreventive MedicineCardiovascular Disease	2017	319
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial Chantal Mathieu, Bernard Zinman, Joanna Uddén, Diabetes Care	2016	301

Page 1